Current research is increasingly focused on integrating metabolic therapies with molecular profiling, such as applying AMPK activators or metabolic diets in patients with obesity, insulin resistance, or specific mutations that confer metabolic vulnerabilities. Here, PRKAB1 is linked to obesity disorder.